ABSTRACT
Sofosbuvir is the first-in-class NS5B nucleotide inhibitor to be launched in hepatitis C virus (HCV) treatment. Its viral potency, pan genotypic activity, and high barrier to resistance make it the ideal candidate to be used in combination with pegylated interferon and ribavirin (PR) and to become a backbone for several interferon (IFN) free regimens. This drug has undergone extraordinary clinical scrutiny, with over 60 individual studies with sofosbuvir in combination with other HCV antiviral drugs. This chapter describes the key clinical uses of sofosbuvir and its combinations.
